India Kidney Cancer Therapeutics Market Analysis

India Kidney Cancer Therapeutics Market Executive Summary

India's Kidney Cancer Therapeutics Market was valued at $114.39 Mn in 2023 and is predicted to grow at a CAGR of 7.86% from 2023 to 2030, to $194.27 Mn by 2030.

A characteristic of renal cancer is the growth of abnormal cells in the renal tissues, which leads to tumors. Symptoms include appetite loss, flank pain, blood in the urine, etc. Tests for blood and urine, biopsies, MRIs, CT scans, and other diagnostic procedures are among them. Potential therapeutic options include medication, radiation therapy, chemotherapy, nephrectomy, and targeted therapy. The key drivers of this industry include rising incidences of kidney cancer, Increased Knowledge of Immunotherapies, and a rise in R&D expenditures by pharmaceutical businesses Source. The industry is primarily dominated by Pfizer Inc., Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Novartis AG, Lupin, Cipla Inc, Aurobindo Pharma UNIQURE N.V. Orchard Therapeutics plc Fibro Gen Inc., Ionis Pharmaceuticals Inc. Alnylam Pharmaceuticals Inc.

In India, 1 in 600 women and 1 in 442 males are estimated to be at risk of kidney cancer. It seems that men are marginally more at risk than women. Furthermore, it is estimated that the incidence of renal cell carcinoma (RCC), which is the most prevalent kind of kidney cancer, is 1 per 100,000 people for females and 2 per 100,000 people for males in India. The incidence of kidney cancer is nearly four times higher than in the West. It is estimated that 2 out of every 100,000 males and 1 out of every 100,000 females are affected by renal cell carcinoma (RCC). The International Kidney Cancer Coalition (IKCC) carried out a global survey in 2020 with the participation of Indian patients and caregivers. The purpose of the study was to learn more about the care experiences of Indian patients with kidney cancer.

Market Dynamics

Market Growth Drivers

Rise in the prevalence of kidney disease: The expanding need for renal cancer treatments is primarily due to the rising global prevalence of chronic renal disease. Chronic kidney disease (CKD) affects about 10% of the population, based on the National Kidney Foundation. Renal cell carcinoma accounts for more than 90% of instances of kidney cancer, whereas renal pelvis cancer accounts for less than 10% of cases with microscopy-confirmed kidney cancer. About 70.0% of the people with renal cell carcinoma, also known as RCC, have clear cell RCC, which is the most common subtype. This suggests a greater need for renal treatment for cancer.

Increased knowledge of immunotherapies: The growing demand for innovative immunotherapies and immune-oncologic drugs will drive the usage of personalized therapies for certain individual subpopulations. Programmed death-1 (PD-1) inhibitors are meant to take the place of TKIs & inhibitors of mTOR as the basis of treatment in first- and second-line RCC cases. Combining regimens, especially those with PD-1 inhibitors, will be used in the first-line scenario to meet significant unmet needs, improve progression-free survival, overcome cancer resistance, and preserve quality of life. Therefore, this type of care promotes the expansion of the market.

Rise in R&D expenditures by pharmaceutical businesses Source: In 2019, the pharmaceutical industry spent an incredible $83 billion on research and development globally. After deducting inflation, this amount is almost 10 times the industry's yearly spending from the 1980s. The number of new medications approved for sale increased by 60% between 2010 and 2019, reaching a peak of 59 new drugs in 2018. The availability of more innovative drugs has increased as a consequence of this rise in R&D spending, benefiting patients everywhere.

Market Restraints

Side Effects and Toxicities: Due to the severe side effects that accompany these medications, it is possible that the renal cancer treatment market won't grow as much as expected in the estimated time frame. A few negative consequences that could impede market growth include rash, fever, or appetite loss.

Excessive health care costs: The high costs connected with these agents prevent the market from growing. Numerous individuals are unable to afford the relatively high cost of generic renal cancer drugs. As such, it hinders market expansion.

Poor reimbursement policies: Inadequate reimbursement regulations make it more difficult for people with kidney cancer to get the medications they need, which raises costs and impedes market expansion. Financial barriers prevent patients from beginning and completing treatment when payment plans do not cover the whole cost of prescription medications. Patients may have to pay substantial out-of-pocket expenses in these situations. These payment constraints further diminish the market potential for kidney cancer medications.

Regulatory Landscape and Reimbursement Scenario

As part of the India@100 strategy, the pharmaceutical business in India is expected to proliferate, with aims of US$450 billion by 2047 and US$130 billion by 2030. Central Drugs Standard Control Organization (CDSCO) is India's main regulatory body for pharmaceuticals and medical devices. Its responsibilities include drug approvals, post-marketing surveillance, and clinical studies. An organization that controls and guarantees the affordability of medication prices is the National Pharmaceutical Pricing Authority (NPPA).

India Council of Medical Research (ICMR), this organization is essential to the advancement of knowledge and the moral conduct of clinical trials. The Department of Biotechnology (DBT) aims to further biotechnology research and development, including developing cancer medications.

The government-sponsored PM program, Pradhan Mantri Jan Arogya Ayushman Bharat Yojana, pays for kidney cancer treatment. Through their health insurance schemes, several states provide coverage for cancer treatment. Many private insurance plans include kidney cancer treatment in addition to other cancer treatments.

Competitive Landscape

Key Players

Here are some of the major key players in the India kidney cancer therapeutics market.

• Pfizer Inc
• Dr. Reddy's Laboratories Ltd
• Sun Pharmaceutical Industries Ltd
• Novartis AG
• Lupin
• Cipla Inc
• Aurobindo Pharma
• Uniqure N.V. Orchard Therapeutics plc FibroGen Inc.
• Ionis Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc